Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is frequently deregulated in breast cancer, driving cell proliferation and survival.
• Single-agent mTOR inhibitors have shown limited antitumor efficacy in clinical settings.

Purpose of the Study:

• To evaluate the therapeutic potential of vertical inhibition of the Akt/mTOR pathway in breast cancer.
• To assess the combined effects of an Akt inhibitor (MK-2206) and an mTOR inhibitor (rapamycin) on breast cancer cell lines and xenografts.

Main Methods:

• In vitro assessment of cell signaling, proliferation, and apoptosis in breast cancer cell lines treated with MK-2206 and/or rapamycin.
• In vivo evaluation of antitumor efficacy using breast cancer xenograft models.

Main Results:

• MK-2206 inhibited Akt phosphorylation, proliferation, and induced apoptosis in a dose-dependent manner.
• Rapamycin inhibited S6 phosphorylation and proliferation, with modest apoptosis induction.
• Combination therapy synergistically inhibited proliferation and induced apoptosis more effectively than single agents, both in vitro and in vivo.

Conclusions:

• Vertical inhibition of Akt and mTOR pathways demonstrates enhanced antitumor activity in breast cancer models.
• Combination therapy with Akt and mTOR inhibitors represents a potentially viable treatment strategy for breast cancer patients.